摘要
目的探讨依达拉奉对急性心肌梗死（AMI）溶栓后肌钙蛋白I和C-反应蛋白的影响。方法将60例AMI患者随机分为治疗组30例与对照组30例。观察两组再灌注后心律失常发生率，测定溶栓后2、24h的磷酸肌酸激酶同工酶（CK—MB）和心肌肌钙蛋白I（cTnI），溶栓后24h、48h、7d的C．反应蛋白。结果两组治疗后24h的CK—MB和2、24h的cTnI及治疗后48h、7d的C-反应蛋白比较差异有统计学意义（P〈0．05）。结论急性心肌梗死时在常规治疗基础上加用依达拉奉，可明显减轻再灌注损伤，改善AMI患者的生存率及预后。
Objective To investigate the effect of edaravone on troponin I and C-reactive protein in acute myocardial infarction （AMI） after thrombolysis. Methods Sixty cases of AMI patients were ran- domly divided into treatment group （n = 30） and control group （ n = 30）. The incidence of reperfusion ar- rhythmias was observed, and the levels of CK-MB and cardiac troponin I（cTnI） at 2 hours, 24 havs, and the levels of C-reactive protein at 24 h, 48 h, 7 d were measured. Results After treatment, there were significantly differences in 24 hour of CK-MB, 2 hours and 24 hours of eTnI and 48 hour, 7 days of C-reac- tive protein levels between the two groups （P 〈 0. 05） . Conclusions Application of edaravone on the basis of conventional therapy, can significantly reduce reperfusion injury in acute myocardial infarction, improve the survival rate and prognosis of patients with AMI.
出处
《中国实用医刊》
2013年第22期18-19,共2页
Chinese Journal of Practical Medicine
